MetaVia (NASDAQ:MTVA) Trading 8.8% Higher – Still a Buy?

MetaVia Inc. (NASDAQ:MTVA) shares traded up 8.8% during mid-day trading on Friday . The company traded as high as $9.68 and last traded at $9.31. 80,665 shares changed hands during trading, a decline of 67% from the average session volume of 241,664 shares. The stock had previously closed at $8.56.

Analyst Ratings Changes

Several analysts have recently commented on MTVA shares. HC Wainwright started coverage on shares of MetaVia in a research report on Thursday, September 4th. They issued a “buy” rating and a $132.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $82.50.

MetaVia Price Performance

The stock has a market cap of $20.48 million, a price-to-earnings ratio of -1.11 and a beta of 0.29. The stock’s 50-day moving average is $9.62 and its 200-day moving average is $8.59.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.86) by $1.32. Analysts predict that MetaVia Inc. will post -3.9 EPS for the current fiscal year.

Institutional Trading of MetaVia

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC grew its stake in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the quarter. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.